Page last updated: 2024-08-24

triazoles and sta 9090

triazoles has been researched along with sta 9090 in 112 studies

Research

Studies (112)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (0.89)	29.6817
2010's	99 (88.39)	24.3611
2020's	12 (10.71)	2.80

Authors

Authors	Studies
Barsoum, J; Bear, M; Du, Z; Foley, KP; Lin, TY; London, C; Ying, W	1
Baer, MR; Bansal, H; Bansal, S; Barsoum, J; Battiwalla, M; Blackman, RK; Foley, KP; Giles, FJ; Kelly, K; Lee, KP; Padmanabhan, S; Proia, DA; Rao, M; Sang, J; Swords, R; Tomlinson, GE; Ying, W	1
Giaccone, G; Neckers, LM; Trepel, JB; Wang, Y	1
Barsoum, J; Bates, RC; Blackman, RK; Foley, KP; Korbut, T; Koya, K; Liu, Y; Proia, DA; Rosenberg, AF; Sang, J; Smith, D; Zhou, D	1
Barsoum, J; Bear, MD; Foley, KP; Inoue, T; London, CA; McCleese, J; Paalangara, R; Ying, W	1
Acquaviva, J; Barsoum, J; Blackman, RK; Du, Z; Foley, KP; Inoue, T; Koya, K; Ogawa, LS; Proia, DA; Sang, J; Sun, L; Tatsuta, N; Wada, Y; Ye, S; Ying, W; Zhou, D	1
Blackman, RK; Foley, KP; He, S; Koya, K; Liu, Y; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Ye, S; Zhang, C; Zhou, D	1
Cicero, G; Gorska, M; Knap, N; Kuban-Jankowska, A; Popowska, U; Sawczuk, W; Sielicka-Dudzin, A; Wozniak, F	1
Barsoum, J; Borgman, CL; Carey, CD; Carretero, J; Chen, L; Foley, KP; Inoue, T; Jimenez, JP; Li, D; Li, YC; Meyerson, M; Perera, SA; Rodig, SJ; Sang, J; Shapiro, GI; Shimamura, T; Sinha, P; Wong, KK; Ying, W	1
Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Zhang, C	1
Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Sequeira, M; Shafi, AA; Smith, DL; Wada, Y; Weigel, NL; Zhang, C	1
Choi, HK; Lee, K	1
Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, RB; Maris, JM; Reynolds, CP; Smith, MA	1
Zhang, HJ; Zhang, L; Zhang, XT	1
Hodi, FS; Marmarelis, ME; Wu, X	1
Bullova, P; Giubellino, A; Landau, M; Lee, MJ; Neckers, L; Pacak, K; Scroggins, B; Sourbier, C; Trepel, JB; Ying, W	1
Bradley, R; Chen, Y; El-Hariry, I; Goldman, JW; Gordon, GA; Guo, W; Inoue, T; Karol, MD; Raju, RN; Rosen, LS; Teofilivici, F; Vukovic, VM	1
Acquaviva, J; Bates, RC; Camidge, DR; Doebele, RC; El-Hariry, I; Friedland, JC; He, S; Jiang, Q; Jimenez, JP; Lovly, CM; Morris, SW; Proia, DA; Sang, J; Sequeira, M; Shaw, AT; Smith, DL; Xue, L; Zhang, C	1
Belani, CP; Bonomi, P; Brahmer, J; Chen, LC; El-Hariry, I; Goldman, J; Guo, W; Harper, H; Horn, L; Huberman, M; Koczywas, M; Paschold, E; Ramalingam, S; Salgia, R; Sandler, A; Sequist, LV; Shapiro, GI; Socinski, MA; Teofilovici, F; Vukovic, V; Webb, T; West, H; Wong, KK	1
Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Smith, DL; Zhang, C	1
Diaz, R; El-Hariry, I; El-Rayes, BF; Farris, AB; Ganji, PN; Landry, J; Mahaseth, H; Nagaraju, GP; Park, W; Proia, DA; Sullivan, PS; Taliaferro-Smith, L; Wen, J; Willingham, F	1
Chrysikos, D; Dimopoulos, MA; Papadimitriou, CA; Psaltopoulou, T; Sergentanis, TN; Zagouri, F	1
Astsaturov, I; Connolly, DC; Golemis, EA; Litwin, S; Liu, H; Maglaty, MA; Martin, LP; O'Brien, SW; Proia, DA; Serebriiskii, IG; Xiao, F	1
Beebe, K; Huang, Y; Miyajima, N; Mollapour, M; Neckers, L; Nonomura, K; Rivas, C; Shinohara, N; Sourbier, C; Tatokoro, M; Trepel, JB; Tsutsumi, S; Yoshida, S	1
Alberobello, AT; Giaccone, G; Lai, CH; Lee, DH; Park, KS; Petricoin Iii, EF; Pierobon, M; Pin, E; Raffeld, M; Wang, Y	1
Acquaviva, J; Bates, RC; El-Hariry, I; He, S; Jimenez, JP; Nagai, M; Proia, DA; Sang, J; Sequeira, M; Shapiro, GI; Smith, DL; Spector, N; Tolaney, S; Zhang, C	1
Chaturvedi, P; Gilkes, DM; Hu, H; Liang, H; Luo, W; Semenza, GL; Takano, N; Xiang, L	1
Acquaviva, J; Bates, RC; He, S; Jimenez, JP; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Zhang, C	1
Yaqub, F	1
Pillai, RN; Ramalingam, SS	1
Bauman, L; Chandarlapaty, S; D'Andrea, G; Drullinsky, P; El-Hariry, I; Fasano, J; Gilewski, T; Goldfarb, S; Haque, S; Hudis, C; Jhaveri, K; Lake, D; Lim, K; Modi, S; Moynahan, ME; Patil, S; Reddington, L; Robson, M; Sugarman, S; Vukovic, V; Wasserheit-Leiblich, C	1
Acquaviva, J; Bates, RC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Zhang, C	1
Bates, RC; Proia, DA	1
Brennan, GT; Relias, V; Saif, MW	1
Jang, SW; Kim, J; Ko, J; Oh, M; Park, E; Park, S	1
Bates, RC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL	1
Acquaviva, J; Bates, RC; He, S; Inoue, T; Jimenez, JP; Knowles, MA; Nagai, M; Ogawa, LS; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Tatsuta, N; Zhang, C	1
Ebi, H; Kita, K; Matsumoto, K; Nanjo, S; Takeuchi, S; Tanimoto, A; Yamada, T; Yano, S	1
Acquaviva, J; Bates, RC; Jimenez, JP; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Zhang, C	1
Bogush, I; Cai, KQ; Efimov, A; Egleston, BL; Golemis, EA; Hensley, HH; Klein-Szanto, A; Nikonova, AS; Plotnikova, OV; Seeger-Nukpezah, T; Serzhanova, V	1
Chen, ZG; Diaz, R; Liu, Y; Magliocca, K; Muller, S; Patel, K; Saba, N; Wen, J	1
Beißbarth, T; Dobbelstein, M; Gaedcke, J; Ghadimi, M; Grade, M; He, S; Kramer, F; Landmann, H; Moll, U; Ogawa, LS; Proia, DA	1
Abrams, TA; Blaszkowsky, LS; Chen, J; Goyal, L; Karol, MD; McCleary, NJ; Sheehan, S; Sundaram, E; Wadlow, RC; Wolpin, BM; Zhu, AX	1
Alese, OB; Diaz, R; El-Rayes, BF; Landry, J; Nagaraju, GP	1
Capanu, M; Cercek, A; Chou, JF; Gollub, M; Proia, DA; Raasch, P; Reidy-Lagunes, D; Saltz, LB; Shia, J; Solit, DB; Vakiani, E	1
Chen, K; Hua, Y; Lian, C; Liang, Z; Liu, H; Lu, J; Ruan, L; Shi, H; Tu, Z; Zhang, P	1
Anderson, GP; Asselin-Labat, ML; Bozinovski, S; Burns, CJ; Donald, A; Dousha, L; Lilja, A; McArthur, K; Nguyen, T; Vlahos, R; Weeden, CE; Wong, ZX	1
Burnett, AK; Hills, R; Lazenby, M; Zabkiewicz, J	1
Bates, RC; Chu, J; Huang, Q; Inoue, T; Liu, Y; Rao, PE; Shin Ogawa, L; Sonderfan, AJ; Ye, J; Ying, W; Zhou, D	1
Andric, Z; Bondarenko, I; Ceric, T; Ciuleanu, T; Felip, E; Fennell, D; Goss, G; Hirsh, V; Khuri, F; Komov, D; Ramalingam, S; Rosell, R; Salgia, R; Samarzija, M; Schmid-Bindert, G; Shapiro, G; Sheldon, E; Spicer, J; Teofilovici, F; Vukovic, V; Wehler, T; Zaric, B	1
Alexandrova, EM; Dobbelstein, M; Li, D; Lozano, G; Moll, UM; Proia, DA; Schulz, R; Xu, S; Yallowitz, AR	1
Seo, YH	1
Hagiwara, M; Hosoya, T; Kato-Sumida, T; Kii, I; Koike, Y; Okuno, Y; Sonamoto, R; Sumida, Y	1
Acquaviva, J; Astsaturov, I; Bates, RC; Chimmanamada, D; He, S; Inoue, T; Jimenez, JP; Khazak, V; Ogawa, LS; Osman, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Tatsuta, N; Ying, W; Zhang, C; Zhang, J	1
Epperly, MW; Gomez-Casal, R; Greenberger, JS; Levina, V; Proia, DA; Wang, H	1
Alarcon, S; Beebe, K; Khamit-Kush, K; Kijima, T; Lee, S; Neckers, L; Prince, TL; Rivas, C; Schwartz, H; Scroggins, BT; Tatokoro, M; Trepel, JB; Tsutsumi, S; Yim, K	1
Cavanaugh, A; Danella, JF; Juengst, B; Sheridan, K; Williams, H	1
Antonarakis, ES; Dzinic, SH; Freeman, S; Heath, EI; Heilbrun, LK; Li, X; Liu, G; Sheng, S; Smith, D; Stein, M; Thakur, MK; Vaishampayan, U	1
El-Rayes, BF; Landry, J; Mezina, A; Nagaraju, GP; Shaib, WL	1
Agyeman, AS; Conzen, SD; Jun, WJ; Kim, CR; Kocherginsky, M; Proia, DA; Skor, MN	1
Anders, RA; Annadanam, A; Ballew, M; Belcaid, Z; Cades, JA; Chettiar, ST; Herman, JM; Kato, Y; Lim, M; Malek, R; Manmiller, S; Nugent, KM; Proia, D; Taparra, K; Tran, PT; Wang, H	1
Diao, L; Komaki, R; Lin, SH; Liu, H; Potter, A; Proia, DA; Qiao, Y; Tailor, R; Wang, J; Wang, Y; Zhang, J	1
Ali, MA; Chavez, M; Cohen, JI; Dowdell, K; El-Hariry, I; Lee, MJ; Proia, DA; Shatzer, A; Tomita, Y; Trepel, JB	1
Bastians, H; Concin, N; Dobbelstein, M; Edmunds, S; Erytch, N; Kramer, D; Moll, UM; Roßmann, L; Schulz-Heddergott, R; Stark, N	1
Alturkmani, H; Baltezor, M; Butte, AJ; Chen, B; Flynn, CA; Godwin, AK; Hyter, S; Ma, Y; Neville, KA; Pessetto, ZY; Rosenthal, HG; Weir, SJ	1
Giaccone, G; Subramaniam, DS; Warner, EA	1
Bullinger, L; Döhner, H; Fröhling, S; Grasedieck, S; Kuchenbauer, F; Miller, C; Reinhart, S; Rouhi, A; Scholl, C; Stolze, B	1
Abe, R; Amoh, Y; Fukushima, S; Hoshina, D; Ihn, H; Jinnin, M; Kajihara, I; Masuzawa, M; Yamada-Kanazawa, S	1
Banerjee, T; Heckert, B; Kallu, J; Naz, S; Santra, S; Shelby, T; Sulthana, S; Vuppala, SR; Yambem, O	1
Fu, L; Gu, Y; Jiang, J; Li, L; Li, Z; Liu, J; Lu, Y; Niu, D; Xia, F; Xu, W; Zhou, Z	1
Agarwal, PK; Hammerich, KH; Hao, JJ; Krane, LS; Li, QQ; Neckers, L; Sanford, T; Trepel, JB; Zhang, Z	1
Alexandrova, EM; Moll, UM; Xu, S	1
Ayers, GD; Berlin, JD; Cardin, DB; Chan, E; Goff, LW; Jones, CM; Thota, R; Whisenant, JG	1
Chen, MH; Chou, TC; Hsueh, C; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN	1
Chen, Z; El-Rayes, BF; Lesinski, GB; Merchant, N; Nagaraju, GP; Wu, C	1
Lee, H; Parris, AB; Saini, N; Yang, X; Zhao, M	1
Abu Jhaisha, S; Becker, W; Kii, I; Knapp, S; Papadopoulos, C; Sonamoto, R; Widowati, EW	1
Allison, JP; Amaria, R; Ashkin, E; Davis, RE; Devi, S; Hanash, SM; Heffernan, T; Huang, L; Hwu, P; Khong, H; Kuiatse, I; Liu, C; Lizee, G; Malu, S; Mbofung, RM; McKenzie, JA; Muller, FL; Peng, W; Proia, D; Roszik, J; Satani, N; Talukder, AH; Tieu, T; Tripathi, SC; Williams, L; Xu, C; Zhang, M	1
Alessandrini, G; Amoreo, CA; Blandino, G; Ciliberto, G; Cioce, M; De Maria, R; di Martino, S; Facciolo, F; Galati, R; Nuvoli, B; Pass, HI; Strano, S	1
Deneka, AY; Gaponova, A; Golemis, EA; Hensley, HH; Kiseleva, AA; Kopp, MC; Korobeynikov, V; Nikonova, AS; Proia, DA; Seeger-Nukpezah, TN; Serebriiskii, IG; Somlo, S	1
Fang, T; Lv, C; Nagle, DG; Wang, JX; Wu, T; Yang, PM; Yuan, X; Zeng, HW; Zhang, C; Zhang, WD; Zhou, YD	1
Burns, TF; Chatterjee, S; Goldstein, LA; Han, J; Hou, W; Rabinowich, H	1
Huang, L; Huang, Y; Huang, Z; Jiang, Y; Liao, Y; Shen, Y; Sun, X; Wei, G; Xu, X; Zhao, C	1
Chen, AP; Do, K; Doroshow, JH; Juwara, L; Kummar, S; Meehan, R; O'Sullivan Coyne, G; Rubinstein, L; Zlott, J	1
Alemà, S; Amoreo, CA; Anastasi, S; Borad, MJ; Buglioni, S; Castellani, L; Cristinziano, G; Egan, JB; Lamberti, D; Leonetti, C; Porru, M; Segatto, O; Shi, CX	1
Acquaviva, J; Bear, MD; Bechtel, SA; Bernabe, LF; Gardner, HL; London, CA; Ogawa, LS; Proia, DA; Sequeira, M; Smith, DL	1
Buchbinder, EL; Chen, T; Flaherty, KT; Giobbie-Hurder, A; Hodi, FS; Ibrahim, N; Jacene, HA; Lawrence, DP; Luke, JJ; McDermott, DF; Ott, PA; Shah, S; Sullivan, RJ	1
He, GL; Li, P; Luo, X; Luo, Z; Shen, TT; Yang, J; Yang, XS	1
Huang, LJ; Peng, Y; Peng, YC; Wang, S; Wang, XL; Zhang, Y	1
Abbey, YC; Agarwal, S; Alilin, AN; Beshiri, ML; Cawley, J; Corey, E; Fang, L; Fuller, C; Guha, R; Hoover, S; Hynes, PG; Jansson, KH; Kelly, K; Klummp-Thomas, C; Lake, R; McKnight, C; Nguyen, HM; Proia, DA; Simmons, JK; Simpson, RM; Stahl, LE; Thomas, CJ; Tice, CM; Tucker, JB; Yin, J; Zhang, X	1
Chang, DJ; Kang, J; Kim, H; More, KN; Park, JH; Taş, İ; Young Lee, J	1
Cahill, FF; Drobnitzky, N; Jiang, Y; Kong, A; Lourenco, LM; Mumin, NH; Patel, A; Ryan, AJ	1
Brown, LE; Chatterjee, S; Collins, C; Cowen, LE; Huang, DS; Hui, R; Hutchinson, A; Krysan, DJ; LeBlanc, EV; Lindquist, S; McLellan, CA; Nation, CS; Pizarro, J; Porco, JA; Robbins, N; Shekhar-Guturja, T; Tatu, U; Trilles, R; Whitesell, L; Xie, JL	1
Almobarak, B; Altiparmak, G; Arvidsson, Y; Elf, AK; Elias, E; Forssell-Aronsson, E; Hofving, T; Johanson, V; Kristiansson, E; Nilsson, O; Sandblom, V; Shubbar, E; Swanpalmer, J	1
El-Rayes, BF; Landry, JC; Lesinski, GB; Nagaraju, GP; Shaib, WL; Zakka, KM	1
Banerjee, T; Darji, S; Fletcher, C; Gerasimchuk, NN; Higginbotham, R; Kallu, J; Santra, S; Sulthana, S	1
Kurihara, E; Namba, K; Ogoshi, Y; Okazaki, M; Sato, H; Shien, K; Shien, T; Soh, J; Suzawa, K; Takahashi, Y; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Yamamoto, H; Yoshioka, T	1
Chen, X; Dai, X; Li, L; Miao, W; Wang, Y; Zhao, Y	1
Li, L; Miao, W; Wang, Y	1
Dou, JP; Liang, P; Liu, FY; Yu, J; Zhai, HY; Zhou, QF; Zhu, XY	1
Abrams, TA; Allen, JN; Carpenter, AN; Chan, JA; Chaudhary, SP; Clark, JW; Enzinger, PC; Goessling, W; Goyal, L; Heist, R; Kwak, EL; McCleary, NJ; Ng, K; Ryan, DP; Schrag, D; Wadlow, RC; Wolpin, BM	1
Addi, L; Alfano, L; Baldassarre, G; Bruzzese, F; Budillon, A; Capone, F; Costa, A; Di Gennaro, E; Iannelli, F; Lombardi, R; Milone, MR; Moccia, T; Pucci, B; Roca, MS; Sonego, M	1
Hayashi, K; Onda, T; Onidani, K; Sekikawa, S; Shibahara, T; Shiraishi, N; Watanabe, K	1
Alexandrova, EM; Eyermann, CE; Haley, JD	1
Özgür, A	1
Banerjee, T; Gross, RA; Naz, S; Santra, S; Totsingan, F; Woody, K	1
Eshleman, JR; Gulla, A; Kazlauskas, E; Liang, H; Matulis, D; Petrauskas, V; Strupas, K	1
Al-Lazikani, B; Antolin, AA; Clarke, PA; Collins, I; Workman, P	1
Golemis, EA; Liu, H; Liu, L; Lu, Z; Shi, X; Tu, Z; Zhang, P	1
Deycmar, S; Georg, D; Kerschbaum-Gruber, S; Mara, E; Pruschy, M; Waller, V	1
Abd-Eldayem, MA; Cavalu, S; Hasan, AM; Saber, S; Yahya, G; Youssef, ME	1

Reviews

10 review(s) available for triazoles and sta 9090

Article	Year
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Current opinion in investigational drugs (London, England : 2000), 2010, Volume: 11, Issue:12 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Evaluation, Preclinical; HSP90 Heat-Shock Proteins; Humans; Mice; Neoplasms; Structure-Activity Relationship; Triazoles	2010
Geldanamycin and its derivatives as Hsp90 inhibitors. Frontiers in bioscience (Landmark edition), 2012, 06-01, Volume: 17, Issue:6 Topics: Animals; Antineoplastic Agents; Benzoquinones; Cyclin-Dependent Kinases; HSP90 Heat-Shock Proteins; Humans; Indoles; Lactams, Macrocyclic; Macrolides; Models, Biological; Mutation; Novobiocin; Proto-Oncogene Proteins c-raf; src-Family Kinases; Transforming Growth Factor beta; Triazoles; Tumor Suppressor Protein p53	2012
Recent updates on the development of ganetespib as a Hsp90 inhibitor. Archives of pharmacal research, 2012, Volume: 35, Issue:11 Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Clinical Trials as Topic; Drug Design; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Protein Folding; Triazoles	2012
[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2012, Volume: 41, Issue:12 Topics: Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Triazoles	2012
Hsp90 inhibitors in breast cancer: a systematic review. Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:5 Topics: Adenine; Antineoplastic Agents; Benzamides; Benzoquinones; Biomarkers, Tumor; Female; Glycine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Indazoles; Isoxazoles; Lactams, Macrocyclic; Pyridines; Resorcinols; Triazoles; Triple Negative Breast Neoplasms	2013
Heat shock protein 90 inhibitors in non-small-cell lung cancer. Current opinion in oncology, 2014, Volume: 26, Issue:2 Topics: Benzamides; Benzoquinones; Carcinoma, Non-Small-Cell Lung; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Isoxazoles; Lactams, Macrocyclic; Lung Neoplasms; Molecular Targeted Therapy; Resorcinols; Treatment Outcome; Triazoles	2014
Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer research, 2014, Mar-01, Volume: 74, Issue:5 Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Triazoles	2014
Organelle-specific Hsp90 inhibitors. Archives of pharmacal research, 2015, Volume: 38, Issue:9 Topics: Animals; Benzoquinones; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Organelles; Triazoles	2015
Ganetespib for small cell lung cancer. Expert opinion on investigational drugs, 2017, Volume: 26, Issue:1 Topics: Animals; Antineoplastic Agents; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Molecular Weight; Small Cell Lung Carcinoma; Triazoles; Up-Regulation	2017
Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice. International journal of molecular sciences, 2023, Mar-06, Volume: 24, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Triazoles	2023

Trials

13 trial(s) available for triazoles and sta 9090

Article	Year
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC cancer, 2013, Mar-25, Volume: 13 Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; HSP90 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Treatment Outcome; Triazoles	2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer discovery, 2013, Volume: 3, Issue:4 Topics: Adult; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays; Young Adult	2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jun-01, Volume: 19, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Genotype; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Triazoles	2013
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical breast cancer, 2014, Volume: 14, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; HSP90 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Triazoles	2014
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Investigational new drugs, 2015, Volume: 33, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; HSP90 Heat-Shock Proteins; Humans; Liver; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Treatment Outcome; Triazoles	2015
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. Clinical colorectal cancer, 2014, Volume: 13, Issue:4 Topics: Adult; Aged; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Survival Rate; Triazoles	2014
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; HSP90 Heat-Shock Proteins; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Taxoids; Treatment Outcome; Triazoles	2015
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Investigational new drugs, 2016, Volume: 34, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; HSP90 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Triazoles	2016
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. American journal of clinical oncology, 2018, Volume: 41, Issue:8 Topics: Adult; Aged; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Triazoles	2018
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. The oncologist, 2018, Volume: 23, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sarcoma; Triazoles	2018
Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 12-15, Volume: 24, Issue:24 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Dogs; HSP90 Heat-Shock Proteins; Leukemia, Mast-Cell; Mice; Oncogenes; Proteolysis; Proto-Oncogene Proteins c-kit; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays	2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma research, 2018, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Female; HSP90 Heat-Shock Proteins; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazoles; Uveal Neoplasms	2018
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Investigational new drugs, 2020, Volume: 38, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; HSP90 Heat-Shock Proteins; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome; Triazoles	2020

Other Studies

89 other study(ies) available for triazoles and sta 9090

Article	Year
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Experimental hematology, 2008, Volume: 36, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Primers; Dog Diseases; Dogs; HSP90 Heat-Shock Proteins; Leukemia, Mast-Cell; Mastocytoma; Mice; Mice, SCID; Proto-Oncogene Proteins c-kit; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Triazoles	2008
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood, 2010, Nov-25, Volume: 116, Issue:22 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoquinones; Cell Line, Tumor; Etoposide; Female; Gene Expression Regulation, Leukemic; Gene Silencing; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid; Mice; Mice, SCID; Proteasome Endopeptidase Complex; Protein Interaction Domains and Motifs; Protein Structure, Tertiary; Triazoles; WT1 Proteins	2010
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PloS one, 2011, Apr-14, Volume: 6, Issue:4 Topics: Animals; Cell Division; Genes, cdc; HSP90 Heat-Shock Proteins; Janus Kinase 2; Mice; Neoplasms, Experimental; Signal Transduction; STAT Transcription Factors; Triazoles; Tumor Cells, Cultured	2011
Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PloS one, 2011, Volume: 6, Issue:11 Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dogs; Female; HSP90 Heat-Shock Proteins; Indoles; Male; Neoplasms; Prodrugs; Tandem Mass Spectrometry; Triazoles	2011
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Molecular cancer therapeutics, 2012, Volume: 11, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemical and Drug Induced Liver Injury; Crystallography, X-Ray; Female; Heart; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; K562 Cells; Lactams, Macrocyclic; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms; Rabbits; Rats; Rats, Sprague-Dawley; Triazoles; Xenograft Model Antitumor Assays	2012
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Investigational new drugs, 2012, Volume: 30, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Paclitaxel; Taxoids; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2012
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18 Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Intramolecular Oxidoreductases; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, SCID; Prostaglandin-E Synthases; Protein Binding; Protein Stability; Triazoles; Xenograft Model Antitumor Assays	2012
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Molecular cancer therapeutics, 2012, Volume: 11, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, ras; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mutation; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays	2012
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. International journal of oncology, 2013, Volume: 42, Issue:1 Topics: Animals; Apoptosis; Benzoquinones; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Flow Cytometry; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Mice; Mice, SCID; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2013
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatric blood & cancer, 2013, Volume: 60, Issue:7 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays	2013
Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PloS one, 2013, Volume: 8, Issue:2 Topics: Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; GTP Phosphohydrolases; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Inhibitory Concentration 50; Melanoma; Membrane Proteins; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Skin Neoplasms; Triazoles	2013
Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PloS one, 2013, Volume: 8, Issue:2 Topics: Adrenal Gland Neoplasms; Adrenal Glands; Animals; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Pheochromocytoma; Rats; Triazoles	2013
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Investigational new drugs, 2014, Volume: 32, Issue:1 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; HSP90 Heat-Shock Proteins; Humans; Inflammation; Mice, SCID; Molecular Targeted Therapy; Protein Stability; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2014
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis, 2013, Volume: 16, Issue:4 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Collagen; Colorectal Neoplasms; Down-Regulation; Drug Combinations; Female; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Laminin; Mice, Nude; Platelet-Derived Growth Factor; Proteoglycans; Rectal Neoplasms; Ribonuclease, Pancreatic; RNA, Messenger; Specific Pathogen-Free Organisms; STAT3 Transcription Factor; Transforming Growth Factor beta1; Triazoles; Vascular Endothelial Growth Factor A; Vesicular Transport Proteins; Xenograft Model Antitumor Assays	2013
Ganetespib AIDS lung cancer survival. Cancer discovery, 2013, Volume: 3, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Triazoles; Xenograft Model Antitumor Assays	2013
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-15, Volume: 19, Issue:18 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Flow Cytometry; Gene Regulatory Networks; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Protein Array Analysis; RNA, Small Interfering; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2013
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer research, 2013, Dec-01, Volume: 73, Issue:23 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cells, Cultured; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Female; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Neoplasms; NIH 3T3 Cells; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Triazoles; Xenograft Model Antitumor Assays	2013
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene, 2014, Oct-02, Volume: 33, Issue:40 Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Synergism; G2 Phase Cell Cycle Checkpoints; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Small Cell Lung Carcinoma; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2014
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jan-15, Volume: 20, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mitosis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2014
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. Journal of molecular medicine (Berlin, Germany), 2014, Volume: 92, Issue:2 Topics: Animals; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1; Immunoblotting; Immunohistochemistry; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neovascularization, Pathologic; Neural Cell Adhesion Molecule L1; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Triple Negative Breast Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2014
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Molecular cancer therapeutics, 2014, Volume: 13, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; HSP90 Heat-Shock Proteins; Humans; Indoles; Melanoma; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sulfonamides; Triazoles; Vemurafenib; Xenograft Model Antitumor Assays	2014
American Society of Clinical Oncology Annual Meeting 2013. The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States	2013
mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Molecular cancer research : MCR, 2014, Volume: 12, Issue:5 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Heat-Shock Response; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Random Allocation; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays	2014
Novel agents for the treatment of pancreatic cancer. JOP : Journal of the pancreas, 2014, Mar-10, Volume: 15, Issue:2 Topics: Antibodies, Monoclonal; Cancer Vaccines; Drug Therapy; HSP90 Heat-Shock Proteins; Humans; Immunologic Factors; Immunotherapy; Mucin 5AC; Pancreatic Neoplasms; Treatment Outcome; Triazoles	2014
The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis. Journal of molecular and cellular cardiology, 2014, Volume: 72 Topics: Animals; Aorta; Atherosclerosis; Benzoquinones; Cell Cycle Checkpoints; Cell Line; Cell Movement; Cell Proliferation; Cholesterol; Diet, High-Fat; Gene Expression Regulation; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Plaque, Atherosclerotic; Primary Cell Culture; Receptors, LDL; Signal Transduction; Triazoles	2014
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Investigational new drugs, 2014, Volume: 32, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Female; Fluorouracil; HCT116 Cells; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Radiation-Sensitizing Agents; Radiation, Ionizing; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays	2014
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Molecular cancer research : MCR, 2014, Volume: 12, Issue:7 Topics: Animals; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Random Allocation; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Triazoles; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2014
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget, 2014, Jul-15, Volume: 5, Issue:13 Topics: Benzoquinones; Blotting, Western; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Hepatocyte Growth Factor; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Ligands; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Transforming Growth Factor alpha; Triazoles	2014
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Targeted oncology, 2015, Volume: 10, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice, SCID; Mutation; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2015
Nedd9 restrains renal cystogenesis in Pkd1-/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, Sep-02, Volume: 111, Issue:35 Topics: Adaptor Proteins, Signal Transducing; Animals; Aurora Kinase A; Calcium Signaling; Cilia; Disease Models, Animal; Epithelial Cells; Female; HSP90 Heat-Shock Proteins; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Polycystic Kidney, Autosomal Dominant; Primary Cell Culture; Triazoles; TRPP Cation Channels	2014
Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Deferoxamine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Oropharyngeal Neoplasms; Papillomaviridae; Triazoles	2014
UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. Cell death & disease, 2014, Sep-11, Volume: 5 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Glucuronosyltransferase; HSP90 Heat-Shock Proteins; Humans; Triazoles	2014
HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget, 2014, Oct-30, Volume: 5, Issue:20 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Colorectal Neoplasms; Down-Regulation; Drug Synergism; Female; Fluorouracil; HCT116 Cells; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; RNA, Small Interfering; Thymidylate Synthase; Transfection; Triazoles; Xenograft Model Antitumor Assays	2014
Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell death & disease, 2015, Jan-15, Volume: 6 Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Mice, Nude; Molecular Targeted Therapy; Radiation Tolerance; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Triazoles; Xenograft Model Antitumor Assays	2015
HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo. PloS one, 2015, Volume: 10, Issue:1 Topics: Animals; B-Lymphocytes; Benzoquinones; Cytokines; HSP90 Heat-Shock Proteins; Inflammation; Killer Cells, Natural; Lactams, Macrocyclic; Lipopolysaccharides; Lung; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neutrophils; Triazoles	2015
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia research, 2015, Volume: 39, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Proto-Oncogene Proteins c-akt; Triazoles	2015
The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus. PloS one, 2015, Volume: 10, Issue:5 Topics: Animals; B-Lymphocytes; Cyclophosphamide; Cytokines; Disease Models, Animal; Disease Progression; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Spleen; T-Lymphocytes; Triazoles	2015
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature, 2015, Jul-16, Volume: 523, Issue:7560 Topics: Alleles; Allografts; Animals; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Female; Histone Deacetylase 6; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Lymphoma; Male; Mice; Molecular Targeted Therapy; Mutant Proteins; Neoplasm Transplantation; Protein Stability; Survival Rate; Tamoxifen; Triazoles; Tumor Suppressor Protein p53	2015
Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ. Scientific reports, 2015, Aug-03, Volume: 5 Topics: Benzofurans; Cell Cycle Proteins; Chaperonins; Drug Evaluation, Preclinical; Dyrk Kinases; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Luciferases; Molecular Chaperones; Mutation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Small Molecule Libraries; Thiazolidines; Triazoles	2015
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors. Molecular cancer therapeutics, 2015, Volume: 14, Issue:11 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Mice, Inbred ICR; Mice, SCID; Microscopy, Fluorescence; Molecular Targeted Therapy; Neoplasms; Resorcinols; Topoisomerase I Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2015
Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition. Oncotarget, 2015, Dec-29, Volume: 6, Issue:42 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Phenotype; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; Time Factors; Triazoles	2015
Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants. PloS one, 2015, Volume: 10, Issue:10 Topics: Adenosine Triphosphate; Amino Acid Sequence; Benzoquinones; Binding Sites; DNA-Binding Proteins; GTP-Binding Proteins; Heat Shock Transcription Factors; HEK293 Cells; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lactams, Macrocyclic; Molecular Sequence Data; Mutation; Protein Binding; Protein Conformation; Protein Isoforms; Protein Kinase Inhibitors; Receptor, ErbB-2; Transcription Factors; Triazoles; Tumor Suppressor Proteins	2015
Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer. Oncotarget, 2015, Nov-24, Volume: 6, Issue:37 Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Muscles; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Purine Nucleosides; Retinoblastoma Protein; Signal Transduction; Triazoles; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms	2015
Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. European journal of cancer (Oxford, England : 1990), 2016, Volume: 52 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; HSP90 Heat-Shock Proteins; Humans; Janus Kinase 2; JNK Mitogen-Activated Protein Kinases; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transfection; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2016
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer. Hormones & cancer, 2016, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Paclitaxel; Receptors, Glucocorticoid; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2016
Ganetespib radiosensitization for liver cancer therapy. Cancer biology & therapy, 2016, 04-02, Volume: 17, Issue:4 Topics: Cell Proliferation; Humans; Liver Neoplasms; Radiation-Sensitizing Agents; Signal Transduction; Triazoles	2016
Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-01, Volume: 22, Issue:23 Topics: A549 Cells; Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoradiotherapy; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Radiation-Sensitizing Agents; Triazoles; Xenograft Model Antitumor Assays	2016
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood. Leukemia & lymphoma, 2017, Volume: 58, Issue:4 Topics: Animals; B-Lymphocytes; Cell Line, Transformed; Cell Survival; Cells, Cultured; Disease Models, Animal; Epstein-Barr Virus Infections; Epstein-Barr Virus Nuclear Antigens; Female; Herpesvirus 4, Human; HSC70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lymphocyte Count; Mice; Mice, SCID; T-Lymphocytes; Triazoles	2017
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell death and differentiation, 2017, Volume: 24, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; DNA Damage; DNA Fragmentation; DNA Helicases; Drug Therapy, Combination; Fanconi Anemia Complementation Group A Protein; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Mitosis; Ovarian Neoplasms; Transplantation, Heterologous; Triazoles; Tripartite Motif-Containing Protein 28; Tumor Suppressor Protein p53	2017
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget, 2017, Jan-17, Volume: 8, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Auranofin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computer Simulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Transcription Factors; Triazoles	2017
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Oncotarget, 2017, Jan-31, Volume: 8, Issue:5 Topics: A549 Cells; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Benzodioxoles; Benzoquinones; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Amplification; Genetic Predisposition to Disease; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mutation; Mutation, Missense; Neoplasms; Phenotype; Proto-Oncogene Proteins p21(ras); Purines; RNA Interference; Transfection; Triazoles	2017
Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway. The British journal of dermatology, 2017, Volume: 177, Issue:2 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bridged-Ring Compounds; Case-Control Studies; Cell Movement; Cell Transformation, Neoplastic; Hemangiosarcoma; HSP90 Heat-Shock Proteins; Humans; Signal Transduction; Skin Neoplasms; Taxoids; Triazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2017
Combination Therapy of NSCLC Using Hsp90 Inhibitor and Doxorubicin Carrying Functional Nanoceria. Molecular pharmaceutics, 2017, 03-06, Volume: 14, Issue:3 Topics: A549 Cells; Acrylic Resins; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cerium; Combined Modality Therapy; Doxorubicin; Drug Carriers; Folic Acid; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Nanoparticles; Rats; Reactive Oxygen Species; Triazoles	2017
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Investigational new drugs, 2017, Volume: 35, Issue:3 Topics: Animals; Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Mammary Neoplasms, Experimental; Mice, SCID; Poly(ADP-ribose) Polymerase Inhibitors; Rad51 Recombinase; Radiation, Ionizing; Triazoles; Tumor Burden	2017
Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. Scientific reports, 2017, 03-15, Volume: 7, Issue:1 Topics: Antineoplastic Agents; Benzamides; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Histones; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Isoindoles; Isoxazoles; Protein Processing, Post-Translational; Proteomics; Resorcinols; Triazoles; Urinary Bladder Neoplasms	2017
Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner. Cell death & disease, 2017, 03-16, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclophosphamide; Disease Models, Animal; Drug Synergism; HSP90 Heat-Shock Proteins; Lymphoma; Mice; Triazoles; Tumor Suppressor Protein p53	2017
Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Oncotarget, 2017, Jun-20, Volume: 8, Issue:25 Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; HSP90 Heat-Shock Proteins; Humans; Mice, Nude; Signal Transduction; Thyroid Neoplasms; Triazoles; Xenograft Model Antitumor Assays	2017
Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. Cancer letters, 2017, 08-28, Volume: 402 Topics: 5-Methylcytosine; Animals; Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Mice, Inbred BALB C; Mice, Nude; MutL Protein Homolog 1; Osteonectin; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction; Transfection; Triazoles; Xenograft Model Antitumor Assays	2017
Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling. International journal of oncology, 2017, Volume: 51, Issue:3 Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Signal Transduction; Stomach Neoplasms; Triazoles; Xenograft Model Antitumor Assays	2017
DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain. Scientific reports, 2017, 07-25, Volume: 7, Issue:1 Topics: Catalytic Domain; Cell Cycle Proteins; Chaperonins; Dyrk Kinases; HeLa Cells; Humans; Metabolic Syndrome; Mutation; Phosphorylation; Protein Conformation; Protein Domains; Protein Folding; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Triazoles; Tyrosine	2017
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature communications, 2017, 09-06, Volume: 8, Issue:1 Topics: Animals; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunotherapy; Interferons; Ipilimumab; Kaplan-Meier Estimate; Melanoma; Mice, Inbred C57BL; T-Lymphocytes; Triazoles; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays	2017
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. Oncogene, 2018, Volume: 37, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cellular Senescence; Cisplatin; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Inbred NOD; Mice, SCID; Pemetrexed; Secretory Pathway; Triazoles	2018
Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2018, Volume: 32, Issue:5 Topics: Animals; Aurora Kinase A; Cilia; Disease Models, Animal; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Knockout; NIMA-Related Kinases; Polycystic Kidney, Autosomal Dominant; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Triazoles	2018
The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. Cell death & disease, 2018, 02-07, Volume: 9, Issue:2 Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Benzoquinones; Biological Products; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; MAP Kinase Signaling System; MCF-7 Cells; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase C; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays	2018
HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC. Autophagy, 2018, Volume: 14, Issue:6 Topics: Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cytoprotection; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Stability; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Domains; Triazoles; Up-Regulation	2018
A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy. European journal of medicinal chemistry, 2018, May-10, Volume: 151 Topics: Animals; Breast Neoplasms; Cell Line; Cell Line, Tumor; Drug Delivery Systems; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Indoles; Isoindoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Reactive Oxygen Species; Triazoles; Zinc Compounds	2018
HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:1 Topics: Animals; Bile Duct Neoplasms; Cells, Cultured; Cholangiocarcinoma; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Microtubule-Associated Proteins; Phenylurea Compounds; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Triazoles	2019
Inhibition of HSP90β by ganetespib blocks the microglial signalling of evoked pro-inflammatory responses to heat shock. The international journal of biochemistry & cell biology, 2019, Volume: 106 Topics: Animals; Cell Line, Transformed; Heat-Shock Response; HSP90 Heat-Shock Proteins; Inflammation; MAP Kinase Signaling System; Mice; Microglia; STAT3 Transcription Factor; Triazoles	2019
Hsp90β inhibitors prevent GLT-1 degradation but have no beneficial efficacy on absence epilepsy. Journal of Asian natural products research, 2019, Volume: 21, Issue:9 Topics: Animals; Anticonvulsants; Benzoquinones; Epilepsy, Absence; Excitatory Amino Acid Transporter 2; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Hippocampus; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Mice; Pentylenetetrazole; Triazoles	2019
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Scientific reports, 2018, 11-22, Volume: 8, Issue:1 Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Genotype; High-Throughput Screening Assays; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Male; Mice; Phenotype; Phosphatidylinositol 3-Kinases; Prostate; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2018
Radiosynthesis, biological evaluation and preliminary microPET study of Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24 Topics: Animals; Binding Sites; Cell Line, Tumor; Click Chemistry; Crystallography, X-Ray; Drug Stability; Fluorine Radioisotopes; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Molecular Docking Simulation; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Transplantation, Heterologous; Triazoles	2018
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. BMC cancer, 2019, Jan-24, Volume: 19, Issue:1 Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Interleukin-6; Janus Kinase 2; Signal Transduction; Small Molecule Libraries; Triazoles; Triple Negative Breast Neoplasms	2019
Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus. Nature communications, 2019, 01-24, Volume: 10, Issue:1 Topics: Animals; Antifungal Agents; Candida albicans; Cell Line; Drug Resistance, Fungal; Fungal Proteins; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Mice; Models, Molecular; Molecular Chaperones; Protein Binding; Protein Conformation; Protein Domains; Recombinant Proteins; Resorcinols; Signal Transduction; Triazoles; Virulence	2019
177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Endocrine-related cancer, 2019, 04-01, Volume: 26, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Female; HSP90 Heat-Shock Proteins; Humans; Lutetium; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Triazoles; Tumor Cells, Cultured	2019
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. International journal of cancer, 2019, 09-15, Volume: 145, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Triazoles	2019
Nanomedicine-Assisted Combination Therapy of NSCLC: New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib. Nanotheranostics, 2019, Volume: 3, Issue:1 Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; CHO Cells; Cricetulus; Humans; Lung Neoplasms; Magnetic Fields; Magnetite Nanoparticles; Nanomedicine; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); Triazoles	2019
Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer research, 2019, Volume: 39, Issue:4 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Signal Transduction; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2019
HSP90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N Nature communications, 2019, 08-09, Volume: 10, Issue:1 Topics: 5' Untranslated Regions; Adenosine; Cell Line, Tumor; Genes, Reporter; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Methylation; Proteomics; RNA, Messenger; Triazoles	2019
High-Throughput Targeted Quantitative Analysis of the Interaction between HSP90 and Kinases. Analytical chemistry, 2019, 09-17, Volume: 91, Issue:18 Topics: HEK293 Cells; High-Throughput Screening Assays; HSP90 Heat-Shock Proteins; Humans; Protein Binding; Protein Kinases; Proteome; Proteomics; Triazoles	2019
Hepatic Microwave Ablation-Induced Tumor Destruction and Animal End Point Survival Can Be Improved by Suppression of Heat Shock Protein 90. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2020, Volume: 39, Issue:6 Topics: Ablation Techniques; Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; HSP90 Heat-Shock Proteins; Liver Neoplasms, Experimental; Mice; Mice, Nude; Microwaves; Survival; Treatment Outcome; Triazoles	2020
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Molecular oncology, 2021, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Platinum; Proteomics; Triazoles; Xenograft Model Antitumor Assays	2021
Heat shock protein 90 as a molecular target for therapy in oral squamous cell carcinoma: Inhibitory effects of 17‑DMAG and ganetespib on tumor cells. Oncology reports, 2021, Volume: 45, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Animals; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Molecular Targeted Therapy; Mouth Mucosa; Mouth Neoplasms; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Triazoles	2021
The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer. Cell death & disease, 2021, 01-26, Volume: 12, Issue:1 Topics: Animals; Breast Neoplasms; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Triazoles	2021
Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells. Journal of chemotherapy (Florence, Italy), 2021, Volume: 33, Issue:8 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Osteosarcoma; Triazoles	2021
Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors. Nanotheranostics, 2021, Volume: 5, Issue:4 Topics: A549 Cells; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cerium; CHO Cells; Combined Modality Therapy; Cricetinae; Cricetulus; Glycolipids; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Triazoles	2021
Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. Pancreas, 2021, 04-01, Volume: 50, Issue:4 Topics: Adenosine Triphosphatases; Antineoplastic Agents; Benzamides; Benzoquinones; Carcinoma, Pancreatic Ductal; Cell Culture Techniques, Three Dimensional; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Isoxazoles; Lactams, Macrocyclic; Molecular Structure; Pancreatic Neoplasms; Resorcinols; Rifabutin; Triazoles	2021
Evolution of kinase polypharmacology across HSP90 drug discovery. Cell chemical biology, 2021, 10-21, Volume: 28, Issue:10 Topics: Binding Sites; Discoidin Domain Receptor 1; Drug Discovery; Evolution, Molecular; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Resorcinols; Triazoles	2021
HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression. The Journal of biological chemistry, 2021, Volume: 297, Issue:2 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Repair; DNA Replication; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays	2021
Ganetespib selectively sensitizes cancer cells for proximal and distal spread-out Bragg peak proton irradiation. Radiation oncology (London, England), 2022, Apr-11, Volume: 17, Issue:1 Topics: Dose-Response Relationship, Radiation; Humans; Neoplasms; Protons; Relative Biological Effectiveness; Triazoles	2022